Risk-based monitoring (RBM) continues to transform clinical development using data insights delivered by innovative technology, enhanced processes and new roles to optimize execution. Biopharma is adopting RBM as the standard execution model for their studies. Quintiles is leading this evolution with an expanded RBM offering, Centralized Monitoring. Learn more about Centralized Monitoring in the Fact Sheet, Accelerate your risk-based monitoring (RBM) benefits with a highly adaptive centralized monitoring offering.
Fact Sheet November 19, 2015